A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC Clinical Trial

Official title:
A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)

Status Not yet recruiting

Clinical Trial Summary

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS < 1%.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced or Metastatic NSCLC

Clinical Trial Details

NCT number	NCT05990127
Study type	Interventional
Source	Akeso
Contact	Zhifang Yao, M.D.
Phone	+86-0760-89873999
Email	clinicaltrials@akesobio.com
Status	Not yet recruiting
Phase	Phase 3
Start date	November 14, 2023
Completion date	November 28, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03037086` - Asia PDL1 Study Among NSCLC Patients	N/A
Recruiting	`NCT05662670` - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03274479` - PBF-1129 in Patients With NSCLC	Phase 1
Recruiting	`NCT03502850` - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03969823` - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC	N/A
Completed	`NCT04207775` - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed	`NCT05631678` - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole	Phase 1
Not yet recruiting	`NCT06461156` - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)	Phase 1
Active, not recruiting	`NCT04143607` - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	Phase 3
Completed	`NCT03414814` - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation	Phase 2
Completed	`NCT04360915` - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects	Phase 1